<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17683" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Anticholinergic Reaction</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Migirov</surname>
            <given-names>Allan</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Datta</surname>
            <given-names>Anita R.</given-names>
          </name>
          <aff>HCA Houston healthcare Kingwood</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Allan Migirov declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anita Datta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17683.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acetylcholine (ACh) is a neurotransmitter that acts on the central nervous system (CNS), the autonomic nervous system (ANS), and at the neuromuscular junction (NMJ).<xref ref-type="bibr" rid="article-17683.r1">[1]</xref> Generally, ACh receptors at the NMJ are nicotinic type while in the CNS and ANS they are usually muscarinic type. As a reminder, these receptors are functionally and structurally different; nicotinic ACh receptors are ligand-gated ion channels, whereas muscarinic ACh receptors are G-protein coupled receptors. Processes that enhance ACh function are termed &#x0201c;cholinergic&#x0201d; while processes that inhibit the action of ACh at its receptors are termed &#x0201c;anticholinergic.&#x0201d; Anticholinergic effects are most commonly the result of medication. These medications should be more appropriately termed "antimuscarinics," as they usually block muscarinic but not nicotinic receptors. At least 600 drugs/medicinal products are recognized to have anticholinergic activity, and the most common of these are responsible for a significant amount of poisoning admissions. Many also contribute to the development of an anticholinergic reaction: a constellation of symptoms resulting from the antagonism of muscarinic receptors throughout the body. The features of the anticholinergic reaction are deducible from an understanding of the normal function of muscarinic receptors at various organs, and the following mnemonic summarizes these effects:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mad as a hatter (delirium)</p>
          </list-item>
          <list-item>
            <p>Blind as a bat (ocular symptoms)</p>
          </list-item>
          <list-item>
            <p>Dry as a bone (anhidrosis/dry mouth/dry skin)</p>
          </list-item>
          <list-item>
            <p>Hot as a hare (fever)</p>
          </list-item>
          <list-item>
            <p>Bloated as a toad (constipation)</p>
          </list-item>
          <list-item>
            <p>The heart runs alone (tachycardia)</p>
          </list-item>
          <list-item>
            <p>Full as a flask (urinary retention)</p>
          </list-item>
          <list-item>
            <p>Red as a beet (cutaneous vasodilation)</p>
          </list-item>
        </list>
        <p>Clinically the most significant feature is delirium, particularly in the elderly, who are most likely to be affected by the anticholinergic reaction.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r3">[3]</xref></p>
      </sec>
      <sec id="article-17683.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>Acetylcholine (ACh) is a neurotransmitter found within synaptic vesicles in presynaptic cholinergic neurons present in the central nervous system (CNS), autonomic nervous system (ANS), and neuromuscular junction (NMJ). It is synthesized within the cytosol of the presynaptic neuron from acetyl-coenzyme A and choline by the enzyme <italic toggle="yes">choline acetyltransferase</italic>. It is subsequently transferred to vesicles within the presynaptic neuron for storage. Upon stimulation of the neuron, ACh vesicles are exocytosed, out of the neuron, and into the synaptic cleft, where it can act on receptors present on postsynaptic neurons. In general, the ACh binds to ACh receptors are nicotinic-type at the NMJ, and muscarinic-type at the CNS and ANS, although some exceptions exist.</p>
        <p><italic toggle="yes">Acetylcholinesterase</italic> is an enzyme in the synaptic cleft, functioning to degrade acetylcholine and decrease its concentration, thereby, decreasing its action on its receptors.<xref ref-type="bibr" rid="article-17683.r1">[1]</xref></p>
        <p>Any process that attenuates the effects of acetylcholine at its receptors, whether by reducing its synthesis or release, increasing <italic toggle="yes">acetylcholinesterase</italic> activity, or inhibiting the receptor, is termed an anticholinergic effect. This activity can result from normal physiology, abnormal pathology, or medication.</p>
        <p>Medications with anticholinergic activity usually affect muscarinic receptors but not nicotinic receptors. There are a limited number of medication classes with antinicotinic properties. Therefore the remainder of this article, "anticholinergic" is used synonymously with "antimuscarinic."<xref ref-type="bibr" rid="article-17683.r2">[2]</xref></p>
      </sec>
      <sec id="article-17683.s3" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>There are at least five subtypes of muscarinic receptors (M1, M2, M3, M4, and M5) present throughout the body. Understanding the general function of each muscarinic receptor at each organ system is necessary to understand the anticholinergic reaction. Additionally, although the general patterns of distribution/function listed below are accepted, new research is still being performed to identify additional locations and functions of the receptor subtypes.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r4">[4]</xref></p>
        <list list-type="order">
          <list-item>
            <p><bold>Brain</bold>: All five (M1-M5) muscarinic receptor subtypes are distributed throughout the brain. However, several studies suggest that the receptor most significantly implicated in the anticholinergic reaction is the M1 receptor. Components of the reaction include delirium, cognitive impairment, dizziness, sedation, and confusion.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Eye</bold>: M1-M5 are present throughout the eye, but M3 predominates. The stimulation of M3 by ACh causes iris sphincter contraction, leading to pupillary constriction (miosis). Anticholinergic toxicity, therefore, leads to improperly-timed pupillary dilation (mydriasis) and blurred vision.<xref ref-type="bibr" rid="article-17683.r4">[4]</xref><xref ref-type="bibr" rid="article-17683.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Glands</bold>
<list list-type="bullet"><list-item><p><bold>Salivary Glands</bold>: M1 and M3 receptors predominate, and stimulation by ACh leads to increased salivation. Anticholinergic toxicity leads to decreased salivation and dry mouth with difficulty swallowing. M4 is possibly present at the parotid glands, but its full effect is currently unclear.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r4">[4]</xref></p></list-item><list-item><p><bold>Sweat Glands</bold>: The M3 receptor predominates at the sweat glands of the skin and stimulation by ACh leads to increased sweating. The anticholinergic reaction leads to a decreased ability to sweat, and therefore, a decreased ability to dissipate heat.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r4">[4]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Heart</bold>: The M2 receptor predominates in the heart and modulates several aspects of cardiac function; slowing down pacemaker activity and atrioventricular conduction (chronotropic), and decreasing cardiac inotropy (contractility). An anticholinergic effect at the M2 cardiac receptor would lead to sinus tachycardia and increased contractility.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Lungs</bold>: The lung contains M1-M4 receptors which play an important role in lung/bronchial function as well as treatment of lung disease.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref>&#x000a0;The muscarinic receptor antagonists play an important role in treating pathology related to the lungs and&#x000a0;are not classically associated with an anticholinergic reaction.<xref ref-type="bibr" rid="article-17683.r6">[6]</xref><xref ref-type="bibr" rid="article-17683.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Gastrointestinal System</bold>: M2 and M3 receptors predominate and under ACh stimulation, increase gastric motility. In the anticholinergic reaction, the motility slows down, which can&#x000a0;result in<bold>&#x000a0;</bold>gastric stasis and constipation.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r5">[5]</xref><xref ref-type="bibr" rid="article-17683.r7">[7]</xref><xref ref-type="bibr" rid="article-17683.r8">[8]</xref><xref ref-type="bibr" rid="article-17683.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Bladder</bold>: M3 is predominantly responsible for detrusor/bladder contraction. M2 may be responsible for inhibiting detrusor relaxation, but the exact role is still unclear. Inhibition during an anticholinergic reaction leads to an inability to contract the bladder, causing urinary stasis and retention. <xref ref-type="bibr" rid="article-17683.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Skin</bold>: Although M3 is the primary receptor at the skin, there is no clear relationship between ACh and vasodilation. ACh can stimulate muscarinic receptors in vascular endothelium, leading to increased nitric oxide synthesis and vasodilation. ACh also acts on nicotinic receptors in the vascular endothelium, leading to vasoconstriction. There is a complex interaction at the vascular endothelium between nicotinic and muscarinic receptors, as well as other factors including norepinephrine and prostaglandins. The anticholinergic reaction generally results in vasodilation at the skin<bold>&#x000a0;</bold>despite the complexity of factors involved,&#x000a0;likely to dissipate excess body heat.<xref ref-type="bibr" rid="article-17683.r10">[10]</xref><xref ref-type="bibr" rid="article-17683.r11">[11]</xref><xref ref-type="bibr" rid="article-17683.r12">[12]</xref><xref ref-type="bibr" rid="article-17683.r13">[13]</xref><xref ref-type="bibr" rid="article-17683.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17683.s4" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>The anticholinergic reaction is thought to be due to both central and peripheral antagonism of ACh at muscarinic receptors.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref> The mechanism of each specific symptom derives from the normal function of ACh at each of its muscarinic receptors (see Organ Systems Involved, above).</p>
      </sec>
      <sec id="article-17683.s5" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>Testing is not available to aid in the&#x000a0;diagnosis of anticholinergic toxicity. &#x000a0;It is a clinical diagnosis based on a thorough history and physical exam. &#x000a0;The anticholinergic reaction can present with symptoms of non-muscarinic drug effects that can further complicate the syndrome. Clinical exam and testing focus on&#x000a0;patient presentation and evaluation for&#x000a0;all possible causes of delirium. Basic screening tests should include a pregnancy test in childbearing age women, drug levels of acetaminophen, and salicylates to rule out common co-ingestions and fingerstick glucose. Electrocardiogram (ECG) is crucial to evaluate the QT and QRS intervals&#x000a0;to rule out cardiotoxicity.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r15">[15]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17683.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>There are over 600 identified medications and medicinal products with anticholinergic activity.<xref ref-type="bibr" rid="article-17683.r8">[8]</xref> Toxicity leads to a significant number of hospital admissions and up to 40% of intensive care unit admissions.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref>&#x000a0;The geriatric population is at the highest risk for anticholinergic poisoning. &#x000a0;Treatment of anticholinergic toxicity is associated with its additional adverse effects.</p>
        <p><bold>Elderly Patients:</bold> The elderly population is most sensitive to the effects of anticholinergic medications. Age is the most significant patient predictor associated with the severity of an anticholinergic reaction. As age increases, there are changes in metabolism, leading to different drug pharmacokinetics and pharmacodynamics. Additionally, many elderly patients may have comorbidities such as pre-existing psychiatric disease that increase their sensitivities to anticholinergic medications and increased risk of drug-drug interaction with other medications.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref><xref ref-type="bibr" rid="article-17683.r16">[16]</xref><xref ref-type="bibr" rid="article-17683.r17">[17]</xref><xref ref-type="bibr" rid="article-17683.r18">[18]</xref><xref ref-type="bibr" rid="article-17683.r19">[19]</xref>&#x000a0;It merits noting that the relationship between age and anticholinergic sensitivity is an association without established causality.<xref ref-type="bibr" rid="article-17683.r20">[20]</xref><xref ref-type="bibr" rid="article-17683.r21">[21]</xref><xref ref-type="bibr" rid="article-17683.r22">[22]</xref> Regardless, delirium and other effects of the anticholinergic reaction are significant in the elderly as it can lead to increased anxiety, falls, decreased activities of daily living, urinary incontinence, decreased nutritional status, and decreased independence.<xref ref-type="bibr" rid="article-17683.r8">[8]</xref><xref ref-type="bibr" rid="article-17683.r23">[23]</xref></p>
        <p><bold>Treatment:&#x000a0;</bold>Management of anticholinergic toxicity starts with stabilization of any emergent conditions related to airway, breathing, and circulation. Specific treatment available for poisoning includes sodium bicarbonate for prolonged QRS intervals on ECG. Delirium is treatable with benzodiazepines. Cooling methods can treat hyperthermia. If the patient is awake and cooperative, activated charcoal can be a consideration. Supportive treatment is typically sufficient for anticholinergic toxicity. Physostigmine is an available antidote, a drug that inhibits the enzyme acetylcholinesterase in the synaptic cleft; this increases ACh in the synapse and allows for competition for inhibited muscarinic receptors.</p>
        <p><bold>Effects of Treatment</bold>: Clinicians should also monitor patients for effects related to treatment. Physostigmine use is controversial given excessive inhibition of acetylcholinesterase which can lead to additional toxicity. Potential symptoms of toxicity categorize into effects on the CNS (coma and seizures), effects on peripheral muscarinic receptors (bradycardia, bronchospasm, gland overactivity, nausea, and vomiting), and effects on peripheral nicotinic receptors (neuromuscular symptoms). The adverse effects of cholinesterase inhibitors should be considered before administration and require close monitoring after administration.<xref ref-type="bibr" rid="article-17683.r2">[2]</xref> Sodium bicarbonate can lead to metabolic alkalosis, electrolyte abnormalities, volume overload, causing worsening of heart failure and respiratory status.<xref ref-type="bibr" rid="article-17683.r24">[24]</xref> Benzodiazepines can cause respiratory depression if used in excessive amounts, although they have a high safety threshold.&#x000a0;</p>
      </sec>
      <sec id="article-17683.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17683&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17683">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17683/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17683">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17683.s8">
        <title>References</title>
        <ref id="article-17683.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira-Vieira</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Guimaraes</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Alzheimer's disease: Targeting the Cholinergic System.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2016</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-15</page-range>
            <pub-id pub-id-type="pmid">26813123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological management of anticholinergic delirium - theory, evidence and practice.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>516</fpage>
            <page-range>516-24</page-range>
            <pub-id pub-id-type="pmid">26589572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dur&#x000e1;n</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Azermai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vander Stichele</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of anticholinergic risk scales in older adults.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>1485</fpage>
            <page-range>1485-96</page-range>
            <pub-id pub-id-type="pmid">23529548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Buccafusco</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Groat</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Fryer</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laties</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Pasricha</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.</article-title>
            <source>Br J Pharmacol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-78</page-range>
            <pub-id pub-id-type="pmid">16751797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerretsen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Rediscovering adverse anticholinergic effects.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>869</fpage>
            <page-range>869-70</page-range>
            <pub-id pub-id-type="pmid">21733482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Price</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fromer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Molen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n-Rodr&#x000ed;guez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?</article-title>
            <source>NPJ Prim Care Respir Med</source>
            <year>2014</year>
            <month>Jul</month>
            <day>17</day>
            <volume>24</volume>
            <fpage>14023</fpage>
            <pub-id pub-id-type="pmid">25030457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampela</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paajanen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hartikainen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huupponen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Central Anticholinergic Adverse Effects and Their Measurement.</article-title>
            <source>Drugs Aging</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>963</fpage>
            <page-range>963-74</page-range>
            <pub-id pub-id-type="pmid">26518014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tune</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic effects of medication in elderly patients.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2001</year>
            <volume>62 Suppl 21</volume>
            <fpage>11</fpage>
            <page-range>11-4</page-range>
            <pub-id pub-id-type="pmid">11584981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ueki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Relationship Between Constipation and Medication.</article-title>
            <source>J UOEH</source>
            <year>2019</year>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-151</page-range>
            <pub-id pub-id-type="pmid">31292358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Zollman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Characterization of muscarinic receptor subtype of rat eccrine sweat gland by autoradiography.</article-title>
            <source>Brain Res</source>
            <year>1991</year>
            <month>May</month>
            <day>31</day>
            <volume>550</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-32</page-range>
            <pub-id pub-id-type="pmid">1888990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golding</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wesnes</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Leaker</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance &#x00026; cognitive function.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>7</issue>
            <fpage>1535</fpage>
            <page-range>1535-1543</page-range>
            <pub-id pub-id-type="pmid">29522648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neligan</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Lipa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lintlop</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature.</article-title>
            <source>Am J Physiol Regul Integr Comp Physiol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>281</volume>
            <issue>4</issue>
            <fpage>R1097</fpage>
            <page-range>R1097-104</page-range>
            <pub-id pub-id-type="pmid">11557615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooke</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ghebremariam</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>Endothelial nicotinic acetylcholine receptors and angiogenesis.</article-title>
            <source>Trends Cardiovasc Med</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>247</fpage>
            <page-range>247-53</page-range>
            <pub-id pub-id-type="pmid">19232953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>McNeely</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic receptor activation augments muscarinic receptor-mediated eccrine sweating but not cutaneous vasodilatation in young males.</article-title>
            <source>Exp Physiol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-254</page-range>
            <pub-id pub-id-type="pmid">27859779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yates</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manini</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Utility of the electrocardiogram in drug overdose and poisoning: theoretical considerations and clinical implications.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2012</year>
            <month>May</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-51</page-range>
            <pub-id pub-id-type="pmid">22708912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Age-related changes in pharmacokinetics.</article-title>
            <source>Curr Drug Metab</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>601</fpage>
            <page-range>601-10</page-range>
            <pub-id pub-id-type="pmid">21495970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stegemann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ecker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kraahs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wohlfart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Breitkreutz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zimmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bar-Shalom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hettrich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Broegmann</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Geriatric drug therapy: neglecting the inevitable majority.</article-title>
            <source>Ageing Res Rev</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>384</fpage>
            <page-range>384-98</page-range>
            <pub-id pub-id-type="pmid">20478411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Leon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients.</article-title>
            <source>Curr Drug Metab</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>635</fpage>
            <page-range>635-46</page-range>
            <pub-id pub-id-type="pmid">21495973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Slonim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: A review of the literature.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>150</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-183</page-range>
            <pub-id pub-id-type="pmid">28507653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>798</fpage>
            <page-range>798-808</page-range>
            <pub-id pub-id-type="pmid">31251824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hafdi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoevenaar-Blom</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Beishuizen</surname>
                <given-names>CRL</given-names>
              </name>
              <name>
                <surname>Moll van Charante</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Gool</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults.</article-title>
            <source>J Am Med Dir Assoc</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-193.e3</page-range>
            <pub-id pub-id-type="pmid">31300339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic Drug Exposure and the Risk of Dementia: There Is Modest Evidence for an Association but Not for Causality.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2019</year>
            <month>Aug</month>
            <day>06</day>
            <volume>80</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31390497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O&#x002bc;Neil</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bettale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kessels</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costantinou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dunagan</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Medications and Patient Characteristics Associated With Falling in the Hospital.</article-title>
            <source>J Patient Saf</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-33</page-range>
            <pub-id pub-id-type="pmid">25782559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17683.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirrakhimov</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ayach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barbaryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chadha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions.</article-title>
            <source>Int J Nephrol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>7831358</fpage>
            <pub-id pub-id-type="pmid">28932601</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
